

## **ERMARIS BIO, PBC TO PRESENT AT SEED SHOWCASE™ 2024**

Ermaris Bio is developing ERM-001, a bispecific Retinol Binding Protein 4 (RBP4)/ transthyretin (TTR) oral therapeutic for Stargardt Disease (STGD1) and dry age-related macular degeneration (dAMD).

WESTLAKE VILLAGE, CA, December 21, 2023 – Ermaris Bio, PBC, today announced that it is presenting at Seed Showcase, part of Biotech Showcase™ 2024. This year, registered attendees can view Ermaris Bio's presentation live during the in-person event, and also access a recorded version beginning January 5<sup>th</sup> 2024. With 24x7 on-demand access, attendees can view recorded presentations at their convenience when scheduling does not allow viewing during the main event week.

Kevin G. McLure, PhD, Founder and CEO, will be presenting Ermaris Bio at Seed Showcase:

Wednesday, January 10, 2024, at 2:50 pm

Ermaris Bio was founded to improve the health span of patients afflicted by diseases that cause blindness. Ermaris Bio is developing a best-in-class orally bioavailable development candidate to treat geographic atrophy (GA), an advanced form of atrophic or dry age-related macular degeneration (dAMD), and Stargardt Disease (STGD1), a rare disease that often affects patients in adolescence.

"This marks an important time in our quest to develop therapeutics that provide maximum benefit to dAMD and Stargardt patients and their caregivers," said Dr. Kevin McLure, PhD, Founder and CEO of Ermaris Bio ([www.linkedin.com/in/kevin-mclure-15464a45/](http://www.linkedin.com/in/kevin-mclure-15464a45/)).

Dr. Konstantin Petrukhin (Professor of Ophthalmic Science at Columbia University in New York City and former Head, Department of Ophthalmics Research at Merck; [www.linkedin.com/in/konstantin-petrukhin-b777427/](http://www.linkedin.com/in/konstantin-petrukhin-b777427/)) added, "RBP4 is an exciting emerging therapeutic target to prevent blindness in patients with Geographic Atrophy and Stargardt Disease. Oral drugs are anticipated to greatly benefit patients and relieve caregiver burden compared to recently approved drugs for Geographic Atrophy which are injected intravitreally into the eyeball."

Dr. Christopher Cioffi (Associate Professor of Chemistry and Chemical Biology and Constance D'Ambra Endowed Chair of Synthetic Organic Chemistry at Rensselaer Polytechnic Institute; [www.linkedin.com/in/christophercioffiphd/](http://www.linkedin.com/in/christophercioffiphd/)) further commented, "Bispecific drugs that bind both components of the RBP4/TTR protein complex are

positioned to both inhibit RBP4 to treat diseases that cause blindness and also stabilize TTR to treat and prevent progression of TTR amyloidosis (ATTR). This bispecific targeting is important for patients because ATTR is a comorbidity in patients with GA and could potentially be exacerbated by just inhibiting RBP4."

Seed Showcase, as part of Biotech Showcase, is produced by Demy-Colton and EBD Group, and is an investor conference focused on driving advances in therapeutic development by providing a sophisticated networking platform for executives and investors that fosters broad geographical investment and partnership opportunities. The conference takes place each year during the course of one of the industry's largest gatherings and busiest weeks.

"We are delighted that Ermaris Bio, PBC, will be joining us in San Francisco and presenting at Seed Showcase this year," said Sara Demy, CEO of Demy-Colton. "Seed Showcase is a prime opportunity for today's cutting-edge entrepreneurs and motivated investors to come together to discover the potential of technologies that will drive the future of the life science industry."

## **ABOUT SEED SHOWCASE**

Seed Showcase is part of Biotech Showcase, which is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place. Investors and biopharmaceutical executives from around the world gather at Biotech Showcase during this bellwether week which sets the tone for the coming year. Now in its 16th year, Biotech Showcase is a well-established, highly respected conference featuring multiple tracks of presenting companies, plenary sessions, workshops, networking, and an opportunity to schedule one-to-one meetings. Biotech Showcase is produced by Demy-Colton and EBD Group. Both organizations have a long history of producing high-quality programs that support the biotechnology and broader life sciences industry.

## **ABOUT ERMARIS BIO, PBC**

Ermaris Bio is an advanced preclinical stage drug development company based in California, focused on developing innovative and accessible medicines for the treatment of diseases causing blindness. The company's pipeline includes ERM-001 and additional discovery stage programs. <https://www.ermarisbio.com>

## **Contact**

Investor Relations

[ir@ermarisbio.com](mailto:ir@ermarisbio.com)

<https://www.ermarisbio.com/>